A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

The Chinese regulatory agency also cleared the study. About AI-081 AI-081 is a PD-1 and VEGF bispecific antibody with best-in-class potential for the treatment of advanced solid tumors.

Boehringer Ingelheim announces the start of the THULITE Phase II clinical study. It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve ...

The BIPAVE-001 Phase 1/2 trial is designed to evaluate the safety, pharmacokinetic, and efficacy of AI-081 in two integrated parts. Part A is an ongoing, first-in-human Phase 1 dose escalation and ...

On June 23, Aclaris Therapeutics initiated a placebo-controlled Phase 1a/1b program for its investigational bispecific antibody, called ATI-052.

Cindy Crawford chatted with PEOPLE about her anti-aging skincare line, Meaningful Beauty, which is on sale for Amazon Prime Day. The supermodel’s top picks include a moisturizer with SPF, a ...

The Phase 1/2 first-in-human, open-label clinical study is designed to assess the safety, tolerability, and preliminary clinical activity of AVZO-1418/DB-1418 as a single agent and in combination ...